GB1585863A - Pharmaceutical lactobacillus preparations - Google Patents

Pharmaceutical lactobacillus preparations Download PDF

Info

Publication number
GB1585863A
GB1585863A GB35599/77A GB3559977A GB1585863A GB 1585863 A GB1585863 A GB 1585863A GB 35599/77 A GB35599/77 A GB 35599/77A GB 3559977 A GB3559977 A GB 3559977A GB 1585863 A GB1585863 A GB 1585863A
Authority
GB
United Kingdom
Prior art keywords
strains
preparation
lactobacillus
medium
inflammation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB35599/77A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SEIKEN KAI FOUNDATIONAL JURIDI
Original Assignee
SEIKEN KAI FOUNDATIONAL JURIDI
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SEIKEN KAI FOUNDATIONAL JURIDI filed Critical SEIKEN KAI FOUNDATIONAL JURIDI
Priority to GB35599/77A priority Critical patent/GB1585863A/en
Publication of GB1585863A publication Critical patent/GB1585863A/en
Expired legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • A61K35/744Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747Lactobacilli, e.g. L. acidophilus or L. brevis

Description

(54) PHARMACEUTICAL LACTOBACILLUS PREPARATIONS (71) We, SEIKEN KAI FOUNDATIONAL JURIDICAL PERSON a legal body organized under the laws of Japan of No. 3-44, Matsuzaki-cho, 2-chome, Abeno-ku Osaka-shi. Osaka, Japan do hereby declare this invention for which we pray that a Patent may be granted to us, and the method by which it is to be performed to be particularly described in and by the following statement: This invention relates to a pharmaceutical preparation which is primarily useful for the prevention of infection or inflammation or combatting of inflammation or infectious diseases, i.e., one of the types of diseases which are hard to cure even by modern medical scientific methods.
According to one aspect of the present invention, there is provided a pharmaceutical Lactobacillus preparation useful for the prevention of infection or inflammation or combatting of inflammation or infectious disease comprising one or more strains of live Lactobacillus whose growth is enabled or promoted by addition of one or more of sodium sulphide, ammonia and acetic acid to at least one of Stephenson-Whetham medium Stephenson-Whetham medium containing vitamins and Stephenson-Whetham medium containing casamino acid, said preparation being substantially free of other bacterial strains.
According to another aspect of the present invention, there is provided a pharmaceutical Lactobacillus preparation useful for the prevention of infection or inflammation or combatting of inflammation or infectious disease comprising one or more strains of live Lactobacillus whose growth is enabled or promoted by addition of one or more of sodium sulphide, ammonia and acetic acid to at least one of Stephenson-Whetham medium, Stephenson-Whetham medium containing vitamins and Stephenson-Whetham medium containing casamino acid; and a carrier and/or excipient.
According to a further aspect of the present invention, there is provided a method of treatment of a non-human mammal for the preparation of infection or inflammation or combatting of inflammation or infectious disease, comprising administering a preparation as defined in either of the last preceding two paragraphs to said non-human mammal.
Intrusion of bacteria into living bodies and their proliferation are referred to as "infection". Once bacteria start proliferating in the living bodies or the latter start showing reactions (called "infectious diseases") thereto, various symptons may be observed such as fever. flare and swelling. The conditions of the infectious diseases may take a turn for the better when medicines such as antibiotics are used adequately at this state. However since administration of the antibiotic too late or in inadequate dosages, premature discontinuance of antibiotic treatment, the consumption of alcoholic beverages or other unexpected conduct by the patient, and various other phenomena (e.g. the phenomenon that the antibiotic does not adequately reach the effected part) can prevent the extermination or removal of bacteria from the infected living bodies. the medical treatment using antibiotics frequently proves unsuccessful. In some cases, the infectious disease may become chronic so that a cure is even more difficult by the present day's medical science.
The Lactohacillus preparation of the present invention (hereinafter referred to as "the present preparation") is especially effective for the treatment of these diseases. By using typical conditions such as nasal inflammation. gastritis or enteritis, alveolar brennorrhea, pudendal laceration and hemorrhoids which are sometimes classified as incurable conditions. the use of the present preparation and examples of medical treatment using the same are explained as follows.
(i) Nasal Inflammation It is frequently observed that patients who catch cold and show nasal fluids discharge are, for some reasons, infected with pathogenic bacteria. Such bacteria proliferate profusely in the nasal sinus and subsequently start producing toxins. The bodily reaction to the toxins cause inflammation which, depending on its degree and type, generally induces the exudation of various substances. When the condition becomes serious, it may become extremely difficult to treat because the nasal fluids become more and more mucous and antibiotics have difficulty in penetrating such mucus or pus. Moreover, even the use of antibiotics in combination with anti-inflammatory enzymes is very often not effective.
Thus, in many cases, nasal inflammation cannot be cured by the use of antibiotics alone.
Further, antibiotic resistant bacteria may appear under such conditions and secondary reactions occur which result in the disease becoming more serious. Surgical excision is one of the medical treatments generally remaining under these circumstances. The adequate use of the present preparation (preferable in this case is such a preparation which is made of an antibiotic-producing strain) is effective irrespective to whether or not surgical treatment has been performed. Thus, when a large amount of the present preparation was applied to the inflammed part (repeatedly if necessary), bacterial substitution took place gradually and, depending on the condition of patients, the pathogenic bacteria appeared to lose their effect as early as the 2nd day or, at the latest, at about the 15th day. It was also observed that a gradual improvement occurred accompanying the abatement of disappearance of inflammation and swelling and the dissolution or decrease of pus and purification at the site of the disease. In this case, however, when 'compounds having bacteridical activity against Lactobacillus (e.g., horse radish, red pepper and curry) and medicines such as antibiotics intrude into nasal sinus, it sometimes happened that the condition of the disease took a turn for the worse. This is primarily due to a fact that these bactericidal compounds prevent the proliferation of Lactobacillus. In such cases. therefore, it is especially important to use the present preparation which has been previously rendered resistant to the above-mentioned compounds.
Nowadays. a combination of antibiotics and anti-inflammatory enzymes is used for the treatment of sinusitis etc. However, even this type of treatment may not be effective enough for patients exhibiting a very heavy pus discharge and surgical treatment may be subsequently performed. However. the present preparation can be used with effect even when the disease has taken a strong hold, without having to operate.
(ii) Appendicitis Infection with pathogenic bacteria is one of the important causes of this disease. In appendicitis sufferers pathogenic bacteria which induce inflammation gradually leak out of the appendix into the upper- and lower-intestinal organs and usually remain there even after appendectomy. In such case, the remaining pathogenic bacteria near the site of the removed appendix survive inveterately. It sometimes happens that patients are infected with bacteria in hospitals. In a sense. such infections are unavoidable and. even though large amounts of antibiotics may be used, the proliferation of pathogenic bacteria cannot be sufficiently prevented. When the present preparation is employed in such situations. it can bring about an early recovery from the disease because the Lactobacllhts strains can, as in the case of the inflammatory diseases. digest or denature the pathogenic bacteria remaining in the body after the operation and also cell or serum secretions or exudates produced by biophylaxis reactions. Anyway. as antibiotics may be frequently used under these situations, the Lactobacilllís strains to be used should preferably be those which are resistant to such antibiotics.
(iii) Gastiins atid enteritis Even nowadavs it is not rare for those patients (e.g. infants and the aged) having a poor resistance to such diseases. to die of marasmus. pathogenic bacteria-induced gastritis and enteritis as well as the inflammatory diseases caused bv bacteria such as enteritis vibrio, dvsenterv bacteria or Sahiotiella. However. patients normally gradually improve in a few days by the adequate use of antibiotics. However. some of these pathogenic bacteria may be resistance to the antibiotics used. In the latter cases. the disease may not be improved by the use of antibiotics alone. but may become more chronic and frequently induce secondary diseases. Thus. it is of the greatest importance to cure the diseases before they become chronic. For this purpose. it is desirable to adminster to the patients a large amount of the present preparation, if required in combination with antibiotics. Moreover, even in the cases where the diseases may be improved in a few days by administration of a suitable drug. the use of the present preparation is recommended because it can bring about an earlier recovery from the disease and at the same time sweep away all the causes thereof.
(iv) Sputum: Sputum is, like pus, formed by the pathological reaction of living bodies. In addition, sputum itself stimulates the living bodies to form more sputum, so that the formation of sputum continues endlessly as the disease worsens. This phenomenon is fundamentally the same as in the case of sinusitis. Even in this case, the Lactobacillus strains of the present preparation can purify the sputum because, as observed in the intestine, they digest, decompose or denature the nutrients contained in the sputum.
(v) Gingivitis: When the inflammed parts of the body are treated with, for example, antibiotics and anti-inflammatory enzymes, there is frequently little success and bacteria still remain alive without being dispelled by the antibiotics, anti-inflammatory enzymes and the biophylaxis reaction of the body. This is frequently the case with alveolar abscesses and, apart from the insufficient therapeutic effects of the drug employed, is due to the fact that the gum tissues are not restored completely at the time when there is a significant decrease in the number of cells of the pathogenic bacteria.
In such cases, the bacteria and pathogenic bacteria which remain in the oral cavity and in gaps in the teeth and gums, multiply to produce a relapse in the patient. Thus, in this type of disease, it is important to administer the present preparation when the amount of pathogenic bacteria has been decreased. By the administration of the present preparation, the quantitative ratio of the remaining pathogenic bacteria to the Lactohacjlltis strains of the present invention is reduced and simultaneously. the conditions or color of the gums which showed the inflammation swelling may be improved significantly.
In other words. when the parts infected must be treated urgently. antibiotics may be employed to kill pathogenic and non-pathogenic bacteria. and therafter the inflammation caused by the biophvlaxis reaction is improved by the use of the present preparation.
(vi) Hemorrh ojds Many theories have been propounded in the past regarding the causes of this condition.
However. the actual causes are now relatively widely accepted.
The main cause has a close relationship with infection by pathogenic bacteria, i.e.. the kinds and quantity of the pathogenic bacteria; and another cause concerns the presence of intestinal bacteria. i.e. fecal infections: a third cause relates to the structure of the intestinal organs or the anus: a fourth cause relates to the degree and frequencv of irritation of affected parts, i.e. constipation and soliditv of excrement: a fifth cause relates to the mode of the bodily reaction (i.e.. the conditions of the wound) and the recuperative ability (i.e. physical constitution): and a sixth cause relates to the degree and scope of blood cogestion.
The wound or laceration and bacterial infection are peculiar to hemerrhoids and it is rare for patients to be afflicted. on account of laceration alone, with serious hemorrhoids which affects their dailv life. Thus. hemorrhoids can be considered to be the inflammation of the anus and its surrounding portions caused primarily bv bacterial infection or by combination thereof with various other of the above causes. Further. the condition and degree of the condition may vary depending on the bacteria. the interrelation with intestinal bacteria. the reactivitv of the body. the degree of irritation and the site of the affected part. However. it is an undeniable fact that. in almost all cases of hemorrhoids. bacterial infection plavs an important role. In this sense. therefore. it should be recognized that hemorrhoids is indicative of bacterial infection. Based on this understanding. hemorrhoids should be considered, like laryngitis or various inflammation caused by laceration of the birth channel. as the most complicated and unclassable type of inflammation which is primarily caused bv bacterial infection.
Hemorrhoids is one of the most incurable diseases and the difficultv in ascertaining the types of pathogenic bacteria which are present. the resistance thereof to drugs. the degree of local osmosis of the pathogenic bacteria and infectiousness thereof render even the choice of drugs quite difficult.
Further. whether a drug is in fact effective for the intestinal bacteria in the body must be decided independently of the bactericidal activitv of the drug because the body is: in anv event. infected with huge amounts of various intestinal bacteria. These two points mal;e the chose of suitable drugs more difficult.
To sum up. first of all. the Lactobacilllls strains which are used in the present preparation have a characteristic abilitv to control or prevent the growth of other living microorganisms.
This fact has been proven during investigations relating to deodorizing excrement. This ability also serves to prevent the growth of. to kill. or to induce bacterial substitution of. the pathogenic bacteria which form the focus of disease in the afflicted part. Moreover. said ability also works effectively against intestinal bacteria. Further, since the Lactobacillus strains of the present preparation kill the bacteria found on and around the inflammed portion and have a protective effect against intestinal bacteria, and also since the balance of power between the Lactobacillus and the intestinal bacteria is shifted in favor of the former thereby decreasing the amount of putretative bacteria in the intestine, the above-mentioned ability of the Lactobacillus strains can lighten the burden which the living bodies must bear for the purpose of phylaxis. In addition, the strong purifying ability of the present preparation has already been proven through the experiments concerning the deodorization of odorous materials.
Further, the strains used in preparing the present preparation include those having strong antibiotic-productivity. In such cases, the present preparation exhibits a very potent ability to prevent the growth of pathogenic or non-pathogenic bacteria and, as a result, hemorrhoids can be frequently improved, or if not serious, cured almost completely by the use of the present preparation.
Hemorrhoids is characterised by a severe irritation and a contamination of the affected parts. Thus, diseases which affect the host so adversely as hemorrhoids are relatively rare.
Such diseases are usually found in infected eyes, the oral cavity, the gums, the throat, the abdominal cavity or the sexual organs, or, in the case of operation patients, in the field of gynaecology.
Concomitantly. although in the foregoing description, pathogenic bacteria have been described as being mainly responsible for hemorrhoids, it is to be noted that hemorrhoids can sometimes be induced by intestinal pathogenic bacteria.
(vii) Pudetidal laceratioti at the time of childbirth Oral administration of the present preparation or the direct application thereof to the affected part is useful for improving the inflammatory symptoms including swelling, flare or pain in the affected area.
We carried out experiments using various Lactobacillus strains, some of which are resistant to drugs or popular condiments and others not. In order to check whether the present preparation had exerted its effects sufficiently, it had first to be ascertained that the inflammation of the living bodies had disappeared completely. However. since chronic inflammatory diseases cannot be cured in a short period. it is virtually impossible with the present day's food to continue living without taking any condiments.until the complete recovery from the disease. For this reason. therefore, in making the present preparation, it is important to use Lactobacillus strains which are resistant to condiments or antibiotics.
The extensive experiments were carried out although only some of these experiments are described herein.
Since the development of bactericidal agents and antibiotics including red prontosil and penicillins. these products have been used extensivelv for the treatment of bacteria-induced diseases because of their effectiveness compared with previous treatments. This is primarily because. when pyogenic infection or suppurative inflammation is present. the Lactobacillus strains of the present preparation can assimilate or denature and finally purify various exudates which are formed at the site where inflammation is observed due to combat between the host organism and various foreign bodies. The present preparation has a high effectiveness and a wide applicability which are almost comparable to those of sulfa agents. antibiotics and anti-inflammatory enzymes. This is primarily because in the case of suppurative inflammation. Lctctobaclllits strains of the present preparation denature, decompose or assimilate as nutrients. and thus clean. exudates formed in the parts of the body in which symptons of infection. as it taught bv pathology. are observed as a result of a battle against various kinds of foreign bodies. to cause the exudates to disappear. as will be apparent from what is stated above.
The present invention is characteristic in that. when administered orally. it can. in some cases. decrease the peculiar odor of excrement at the time of their evacuation. That is. even in an intestine containing more than loll cells of microbes forming their own peculiar mass of spores. the present preparation can proliferate well and predominate over said microbes. This is because the Lactobclcilllls strains of the present invention can grow faster than almost all intestinal bacteria. require low nutrients, can simultaneouslv produce antibiotics: and therefore can survive in growth. competition with intestinal bacteria. The odorous material in excrement comprise many types of compounds such as various amines. lower fatty acids. ummonin and sulfur compounds. When the amounts of such compounds exceeds a certain limit. they become poisonous to living bodies. The deodorizing effect of the present preparation for these compounds clearlv indicates that it can digest or denature these materials thereby decreasing the amount of the latter or converting them to other materials. Nloreover. these effects of the present preparation are obtained in the presence of a large amount of intestinal bacteria which produce the odorous materials. while preventing the growth of such bacteria. Accordingly, said effect is one of the most important points of the present invention, and said characteristic effect or ability is displayed quite satisfactorily even in other affected parts or infectious diseases. Further, since the Lactobacillus strains of the present invention (which utilize as their nutrients the cells or exudate excreted by various part of the body) can grow very rapidly, the substitution thereof for other bacteria can proceed without hindrance from the latter.
Some of the examples of the medicinal treatment mentioned above indicate that the Lactobacillus strains of the present preparation can predominate over the pathogenic bacteria in the growth competition thereof with said bacteria. Further, the purification action of the present preparation has already been proven through the experiments of deodorization (Deodorization is one indication of the purification action). Thus, the Lactobacillus strains can temporarily proliferate profusely, but their growth may be minimized as the nutrient sources thereof (i.e., the exudate from the inflammed parts) disappear.
In summing up the effects of the present preparation: unlike the antibiotics which serve only to kill the bacteria, the present preparation is characteristic in that (a) it is non-pathogenic; (b) it can produce antibiotics thereby killing bacteria; (c) it can survive in the growth competition with pathogenic or other bacteria; (d) it denatures the metabolites (including poisonous ones) of living bodies or converts them into constituents of its own cells; (e) it purifies an affected part; (f) it shows anti-inflammatory or anti-swelling activities; and finally (g), as said preparation is foreign to the living bodies and is non-pathogenic, it is finally digested after the inflammatory diseases disappear. Accordingly, as is clear from the aforementioned discussions about the causes of the diseases or from the experimental data thereof, the present preparation can be used extensively to give better therapeutic effects, except where it is physically not possible to use it.
Moreover, we have ascertained that these therapeutic effects of the present preparation are sometimes increased when used in combination with enzymes having antiinflammatory, anti-swelling or abating activities. Namely, although it is impossible to sweep away microbes by the use of the enzymes having such activities. and although antibiotics only alleviate the swelling induced by inflammatory diseases or have an insufficient effect thereon, diseases can be frequently improved very significantly by the use of the present preparation because of the bacterial substitution which takes place.
Turning now to the non-pathogenic property of the strains used in the present preparation. Originally, the history of bacteriology began with Pasteur's study of lactic acid bacteria. Despite that fact that many investigations about Lactobacillus have been carried out since 1857, it can be said that any scientific reports have not proven positively that this group of strains is pathogenic. Moreover, not only the current reliable dissertations show the Lactobacillus to be non-pathogenic. but Bergey's Manual (1974) also discloses specifically that pathogenic bacteria belonging to said groups are extremely rare.
According to the inventor's investigations, it has been proven that the presence of Lactobacillus is almost essential to the body, e.g., to the mucous membrane, particularly in the oral cavity, the intestine and the vagina. For example, it is almost impossible for normal conditions to be maintained in the vagina if Lactobacillus is not present therein. Therefore, whether or not Lactobacillus is present has recently been an important check-point in making a diagnosis of the health condition of the vagina. The present preparation shows a distinct effect upon deodorization of the vagina.
Although the strains which are used in the present invention belong to the group of Lactobacillus,whether or not they are pathogenic has not previously been known because they have previously unknown properties.
The fundamental problem to be determined first is whether or not the strains of the present preparation are in fact Lnctobacillus strains. If they are Lactobncilli this fact alone indicates with a very high probability that they are non-pathogenic.
All the morphological properties of the new strains are. except for the nutritional requirements. identical with those of the known strains of Lactobacdliis. The Lnctobncillus strains known heretofore can be defined as gram-positive. facultative anaerobes and non spore-forming rods. Their shapes varv. depending on the strain, from spherical rod-like to curved rod-like. corvne-like or thread-like, but they do not form many branches. Thev are usually non-motile. negative to catalase, do not reduce nitrates. do not decompose gelatin and do not form indole or H2S. Some strains are bipolar-stained. The ability of the Lnctobncillus strains to decompose proteins and lipase is very poor. if not non-existent.
Thev show better growth under an aerobic or slightly aerobic conditions than under fullv aerobic conditions. They decompose sugar strongly and are acid-fast bacteria. Lactic acid is produced in a vield of more than 50roc bv the glucose fermentation thereof. According to the known morphological classification, the strains of the present preparation having these properties should be considered as belonging to the group of Lactobacillus. Moreover. the morphology of microorganisms has not provided a clue to classify microbes according to the difference in the nutritional requirements thereof. At least at present. therefore, it is considered that the strains of the present preparation are Lactobacillus strains. The fact that the strains of the present preparation are considered to be Lactobacllhts strains is of special importance in discussing the non-pathogenic property thereof.
The reason why we selected Lactobacillus in seeking deodorizing microbes for oral administration. despite the fact that other bacetria, such as strains of Pseudomonas, were thought to be available more easily, was that it was thought this group of microbes could provide useful strains. particularly as Lactobacilli are important members of intestinal bacteria. In fact. although at the initial stage of experiments. a great deal of concern was expressed that the deodorizing microorganisms isolated might. when administered orally, exert a bad influence on regular evacuation and other daily life. it was because of this concern about the non-pathogenic property and usefulness thereof that caused the continuation of the various experiments.
First of all, we carried out experiments using various dogs. Then. at the final state of the experiments. washed culture clots (wet 0.1 g/kg) were administered to both human subjects and dogs almost every day or sometimes at intervals of 2 to 3 days for 2 vears. But no pathogenic effects were observed during the experiments. and the human subjects tested showed a decreased fatigue and an improvement in their health as subjective symptoms.
Moreover. 2 dogs which had always been under the veterinary care recovered their health and were able to continue life without veterinary care.
Accordingly, the strains of the present preparation when administered orally to human beings show neither acute. sub-acute nor chronic tonicity. Moreover. when one mg/g of said strain suspended in 3-fold volume of a physiological saline solution was injected intraperitoneallv to 50 mice. as compared with a control group the tested mice did not show any frregular symptons 34, 48 or 72 hours, one week, one month or 3 months after the administration. This indicates that the strains of the present preparation may not show any acute or sub-acute tonicity even by peritoneally administering 60 g of the clots of the microbial cells to human beings of 60 kg body weight. Therefore. the present preparation is considered to be substantially free from pathogenic property.
Next. the properties of the Lactobacllliis strains of the present preparation isolated and cultivated herein. and the method of preparation thereof. are given hereinafter.
(a) Bile resistance In order for the Lactobacillus strains to show their activity sufficiently in the intestines. it is preferable that said strains can grow in the presence of bile.
The bile resistance of the typical strain 1946 F.R.I. used in the present preparation is shown in Table I.
Other typical strains of the Lactobacillus, i.e., 2779/F.R.I., 2780/F.R.I., 2781/F.R.I. and 2782 F.R.I., where have been isolated successfully by the inventor and are usable in the present preparation show almost the same bile resistant properties as 1946/F.R.I. That is. thev can proliferate well in a medium containing 4 by weight <RTI ID=
(b) Nutritional requirements: Unlike the known strains of Lactobacillus which require amino acids, peptides, nucleic acids, vitamins, salts, fatty acids or their esters and sugars for their growth, the Lactobacillus strains of the present preparation show low nutritional requirements.
Nevertheless, they show good growth within a short period of time (such as 2 days) and form lactic acid. Table 2 shows the degree of multiplication thereof in each of various media. S-W medium and S-W + Agar medium were used as the basic media therein.
TABLE 2 Compounds Strains (F.R.I. Nos.) added to Basic the basic medium 1946 2779 2780 2781 2782 medium No (A) - - - - - addition (B) - Sulfur- (A) + - - + containing (B) ++ + - + + amino acids Cyclic amino (A) - - - - - acids (B) - - - - - Branched amino (A) - - - - acids (B) - - - - (A) + - - - Cysteine (B) ++ + - + - (A) + - - - Cystine (B) ++ - - + (A) + - - - Methionine (B) + - - + Casamino (A) + - - + acids (B) ++ + + + + Casamino acids (A) + + + + + + Vitamins (B) ++ + + ++ + Casamino acids + yeast (A) ± + + + + extracts (B) ++ + + ++ + Yeast (A) + + + + + extracts (B) + + + ++ + Note: (A) : S-W medium (B) : S-W medium (+ Agar) + : Normal growth ++ : Good growth +++ Very good growth - . Poor growth - : No growth (c) Specific growth rate: As seen in Table 3. the Lactobacilus strains of the present preparation show surprisingly high specific growth rates even in media of low nutritious conditions. Just for comparison. the specific growth rate of Escherichia coli are shown in the table.
TABLE 3 Nutritional requirements and relative growth rate Basic medium: S-W medium) Strain Ingredients S,N,C and 11 in case of Nos. added to the sulfur- It Escherichia F.R.I. basic medium containing coli amino acids 1946 Sulfur- Yes 0.53 0.4 containing amino acids 2779 Vitamines, Yes 0.46 0.43 sulfur containing amino acids 2780 Vitamins Yes 0.46 0.38 2781 S,N,C Yes 0.53 0.35 2782 Vitamins, Yes 0.46 0.43 sulfur containing amino acids Note S : S-compounds Na2S or H2S N: N-compounds ammonia, indole or scatole C : C-compounds lower fatty acids e.g.(acetic acid or butyric acid) Yes: essential for growth Thus, although the known strains of Lactobacillus show high nutritional requirements and lower growth rate as compared with pathogenic bacteria, the Lactobacillus strains of the present preparation can predominate over the generally known pathogenic bacteria in the growth competition therewith.
(d) The results of microscopic observation and the morphological characteristics of the Lactobacllhts strains of the present preparation are shown in Table 4. Tables 5 and 6 show the biochemical properties and the ability to decompose sugars. respectively.
TABLE 4 Microscopic observation and morpho logical characteristics F.R.I. Nos 2779 2780 2781 2782 1946 Gram + + + + + Shape short rod cocco- cocco- short rod short rod ,rounded bacilli, bacilli, rounded ,rounded ends, no no flage- no flage- ends, no ends, no flagella ila and lia and flagella flagella and no spore no spore and and no spore no spore no spore Capsule No No No No No Motility No No No No No O, anaero- anaero- anaero- anaero- anaero bic bic bic bic bic In a medium round round round round round of normal brothmiddle middle middle middle middle agar medium +colonies colonies colonies colonies colonies sugar + vitamins Semi- Semi- Thin Thick Thick Projection spherical spherical Surface smooth smooth smooth smooth smooth moistened moistened moistened moistened moistened Circum- Plain plain plain plain plain ference Color milkv milky white. milky milky white. white. not white, white. not not transpa- not not transpa- transpa- rent. transpa- transpa rent. rent. mucous rent. rent. mucous mucous mucous mucous TABLE 5 (General properties) F.R.I. Nos 2779 2780 2781 2782 1946 Ammonia-production - - - - - H2S-production - - - - Catalase-production - - - - - Pigment-production - - - - - Gelatin liquefaction - - - - - Utilization of citric acid - - - - - Decomposition of urea - - - - - M.R. reaction + + + + + V.P. reaction - - - - - Reduction of nitrates - - - - - TABLE 6 (Ability to decompose sugars) F.R.I. Nos.
2779 2780 2781 2782 1946 Glucose + + + + + Galactose + + + + + Fructose + + + + Salicin + + + + Arabinose - + - - Xylose - - - + Sucrose + + + + + Inositol - - - - Dextrin + + # # - Mannitol - - - - Melebiose + + + + + Ribose + + + + Lactose + + + + + Raffinose - - + + Starch + + + + + Inuline - - - - Sorbitol - - - + Maltose + + + + + Melezitose - - - - Mannose + # + + Antibiotic-production Although some strains of Lactobacillus have been known to show an antibiotic production. all the strains specified herein have this antibiotic production. This antibiotic production of the preferred Lactobacillus strains serves to prevent the growth of other bacteria or the formation of pus. sputum, serum and other poisonous material.
Table 7 shows one example of the inhibitory effects against bacteria which were estimated bv placing a trace of Lactobacillus strain of the present preparation at the center of a petri dish containing (normal broth agar medium + sugar + vitamins0-medium. cultivatïng it at 37 C for 2 days, and then spreading Staphylococcus aureus (as a representative example of gram-positive bacteria) or Escherichia coli (as a representative example of gram-negative bacteria) on the medium. In actual cases, however, depending on the components of the media and the methods of cultivation or storage, it may sometimes happen that the strains of the present invention show greater antibiotic production than those indicated in Table 7 or do not show any antibiotic production.
TABLE 7 Bactericidal activity Strains Inhibition diameter (pre-cultivated for 48 hours (F.R.I. Nos.) Staphylococcus aureus Escherichia coli 1946 20 mm 24 mm 2772 25 mm 18 mm 2780 15 mm 20 mm 2781 12 mm 15 mm 2882 18 mm 22 mm (f) Table 8 shows that the Lactobacillus strains used in the present preparation are, though varying with the basic media employed, promoted in their growth by the addition various odoriferous ingredients of excrement to the media. Additionally, similar results were obtained by adding S, N or C-containing substances other than those shown in said Table.
The fundamental bacteriological differences between known Lactobacillus, strains and those of the present preparation will now be explained using the data shown in Table 9-(a), Table 9-(b) and Table 9-(c). First of all, the degree of multiplication of known Lactobacillus strains and those of the present preparation under low, middle or high nutritional conditions as well as the changes or degree of changes of their multiplication in the presence of acetic acid are shown in Table 9-(a). This table indicates the clear difference between both groups. Thus. although the addition of a suitable amount of acetic acid to a good nutritional medium (e.g., Briggs' medium which is a typical one for Lactobacillus) is known to promote the growth of the known strains of Lactobacillus, such phenomenon can be observed only in good nutritional media. In other words, since known Lactobacillus strains cannot grow in a low nutritional medium. the addition of acetic acid never serves to stimulate the growth thereof. On the contrary. multiplication of the Lactobacillus strains of the present preparation is strongly promoted by adding a suitable amount of acetic acid to the low or relatively low nutritional media shown in Table 9-(a): but in good or relatively good nutritional media the degree of stimulation to the growth is slight or even non-existent by addition of acetic acid.
Moreover, as seen in Table 9-(b). when known Lactobacillus strains and those of the present preparation are cultivated in low. middle or high nutritional media containing Na2S 9 H2O or NH3, the multiplication of the strains of the present invention in low middle nutritional media is stimulated by addition of 0.1 g or 1 g of NaS'9H20, whereas said addition to the low, middle or high nutritional media does not stimulate the growth of known Lactobacillus strains.
Further, the multiplication of the Lactobacillus strains of the present preparation in low or middle nutritional media is stimulated by the addition of NH3. whereas the growth of known Lactobacillus strains is minimized by addition of even a small amount (e.g. 1 g/l) of Na,S-9H2O or ammonia.
Thus. it is clear that. unlike the known strains, the Lactobacillus strains of the present preparation show new and special behaviors to Na,S and ammonia under low or medium nutritional conditions.
Furthermore. the multiplication of the Lactobacillus strains of the present preparation in low. middle or high nutritional media are stimulated by addition of a mixture of Na.S-9H2O, ammonia and acetic acid. whereas the addition of said mixture to low. middle or high nutritional mediua never serves to stimulate the multiplication known strains of Lactobacjllits(Table 9-(c)).
Also in Tables 9-(a) to (c) it should be noted that the Lactobacillus strains of the present preparation, explained above as those whose growth is promoted in the presence of S.N. and C-containing substances. include a group of strains which can only grow in the presence of said substances.
TABLE 8 Compounds Basic Strains (F.R.I.Nos) added to the medium basic medium 1946 2779 2780 2781 2782 A - - - - B - - - - No addition C + + + + + D ++ ++ ++ ++ ++ A - - - - B + - - + Acetic acid C ± ± ± ++ + D ++ ++ ++ ++ ++ A - - - - Ammonia B + - - - - C ± ± ± ++ + D ++ ++ ++ ++ ++ A - - - - Propionic acid B + - - + C ± ++ ± ++ + D ++ ++ ++ ++ ++ A - - - + B ++ - - + Na2S.9H2O C ++ ± ± ++ ++ D ++ ++ ++ ++ ++ A - - - - Butyric acid B + - - + - C ++ ++ ± ++ + D ++ ++ ++ ++ ++ A - - - - Scatole B + - - - C + + ± ± + D ++ ++ ++ ++ ++ A + + + + + Exeremental B ± + + + + juice C ++ ± ± ± + D ++ ++ ++ ++ ++ Note: (A): S-W medium (B): S-W medium (+ Agar) (C): Peptone 8 g + Glucose 2 g (D): Peptone 10 g + Meat extract 5 g + NaCI 5 g + Glucose 1 g.
TABLE 9-(a) Degree of stimulation Amount of Degree of stimulation of Basic of Lactobacillus acetic Lactobacillus medium Known Strains of acid Known Strains of strains the added strains the invention (g/liter) invention 1 - + Low - + 2 nutrition 5 - ++ 1 - + - + 2 Low 5 + + Middle 1 - nutri- Middle - + + 2 - + tion 5 + 1 - High - ++ 2 - - 5 + + 1 - High + ++ 2 + - nutrition 5 ± + TABLE 9-(b) Amount Degree of stimulation Amount of Degree of stimulation Basic of of Lactobacillus ammonia of Lactobacillus medium Na2S.9 in the presence added in the presence H2O of Na2S.9H2O (g/l) of ammonia added Known Strains of Known Strains of (gil) strains invention strains invention 0.1 - - 0.1 - Low 1 - - 1 - - nutrition 2 - - 2 - 0.1 - - 0.1 - Low 1 - - 1 - - 2 - - 2 - Middle 0.1 -* - 0.1 - nutri- Middle 1 - @ + 1 -* @- tion 2 -* -* 2* -* 0.1 - - 0.1 - High 1 -* + 1 -* 2 -* -* 2 -* High 0.1 - - 0.1 - nutrition 1 -* - 1 - 2 - - 2 - Note: -@: bacterial growth suppression.
TABLE 9-(c) Amount of compounds Degree of stimulation of added (g/l) Lactobacillus in the Basic Na,S NH3 Acetic presence of S, N, C medium 9H,O acid substances Known strains Strains of the invention 0.1 + 0.1 + 0.1 Low 1 + 1 + 1 - + nutrition 2 + 2 + 2 - 0.1 + 0.1 + 0.1 Low 1 + 1 + 1 + + 2 +2 +2 - -* Middle 0.1 + 0.1 + 0.1 nutri- Middle 1 + 1 + 1 -* + tion 2 + 2 + 2 - * - * 0.1 + 0.1 + 0.1 High 1 + 1 + 1 -* 2 + 2 + 2 -* -* 0.1 + 0.1 + 0.1 High 1 + 1 + 1 - nutrition 2 + 2 + 2 - * The low, middle and high nutritional media shown inTable 9 are each defined as those which are obtained by classifying the nutritional requirements of known Lnctobscillus strains or those of the present preparation into three groups, and the middle nutrition into further three groups. while taking into account the biological properties thereof. More specifically. the low nutritional medium shown herein refers to a medium containing (S-W) + vitamins or (S-W) +Casamino acids (vitamin-free) at most. Of course, in the medium. other specific vitamins or amino acids may be used in place of said vitamins or casamino acids; or alternatively a medium not containing both of said ingredients may be used.
Namelv. the low nutritional medium described herein should be interpreted as referring to all the media which do not contain more nutrients than those described above.
On the other hand. the low nutrition of the middle nutritional medium shown in Table 9 refers to (S-W) + vitamins + sulfur-containing amino acids: and the middle nutrition of the middle nutritional medium refers to (S-W) + vitamins + casamino acids, peptone + sugars. or a medium of almost the same nutritional value. The high nutrition of the middle nutritional medium refers to those which consist of the same ingredients as those of the high nutritional medium but which contain only 1/5 to 1/3 nutriments of the latter. In this connection. however. a medium in which some other vitamins and amino acids are added to (S-W)-medium in place of the vitamins and casamino acids used may also be employed as the middle nutritional medium.
Further, the high nutritional medium stated hereinbefore refers to any of the media which are. as already disclosed in various scientific reports. especiallv suitable for proliferation of the known Lactohncillles strains. And such media include not only MRS-medium. but also those which contain amino acids. peptides. nucleic acids. vitamins, minerals. fatty acids or their esters and/or sugars in good nutritional proportions suitable for growth of known Lactobacillus strains.
Anyway. it should be understood that the Lactobacillus strains of the present preparation are not limited to the five strains mentioned above but include any strains which have the same morphological characteristics and nutritional requirements as defined hereinbefore. though the therapeutic effects thereof may vary depending on the actual strain.
Additionallv. while the antibiotic-productivitv of the strains of the present preparation is important in aiding the therapeutic effects thereof indirectlv. it has been ascertained in our experiments that strains having no such productivity also show their effects quite satisfactorily.
The following Examples illustrate making the present preparation.
(i) A Lactobacilllls strain having the hereinbefore defined morphology and nutrional properties was inoculated into a medium (pH 7.4) containing the following ingredients: Skim milk Yeast extract CaCO3 The medium was cultivated by allowing it to stand at 370C for 3 days. Then, the medium was centrifuged under cooling and the collected microbial cells were freeze dried in vacuo, whereby a pharmaceutical Lactobacillus preparation was obtained.
(ii) A Lactobacillus strain having the hereinbefore defined morphology and nutritional properties was inoculated into a medium (pH 7.4) containing the following ingredients: S-W medium* Components of S-W medium: Na2S 9H20 ig KH2PO4; 0.7g MgSO4.7H2O; 1g NaCI; 4g (NH4)2HPO4; 0.03g FeSO4 7H2O; and 5 g glucose.
*S-W medium indicates Stephenson-Whetham medium.
Propionic acid Butyric acid Yeast extracts Vitamins Amino acids The medium was cultivated by allowing it to stand at 37"C for 3 days. Then, the microbial cells were carefully dried until the water content thereof becomes 2%.
The following Examples illustrate the use of the present preparation, Example I The present preparation was administered to three patients suffering from acture sinusitis, five patients suffering from chronic sinusitis and two patients suffering from post-operative sinusitis by dissolving 20 g of the above preparation (water content: 2%) in 400 ml of water, and washing the nasal sinuses of the patients with the resultant solution twice a day for 21 consecutive days. Further, for two patients who had a viscous nasal mucus discharge, the present preparation was used together with tetracycline. Based On (1) subjective symptons (rhinostenosis, post-nasal discharge, nasal discharge, depression in the sense of smell and headache). (2) a pathological observation of nasal sinus and nasal mucous membranes (colour of mucous membranes swelling, amount of nasal discharge, nature of nasal fluids) and (3) direct and X-ray examination, the therapeutic effects of the present preparation were estimated as 4 points (remarkably effective) 2 points (effective), 1 point (slightly effective) and 0 point (ineffective). Table 10 shows the effects of the present preparation at one and 3 weeks after the treatment was started.
TABLE 10 (One week after the treatment was started) Additional subjec- Patholo No. Initial Age Sex Name of Drug tive gical X-ray Average of Name disease used symptom observation 1 M.O. 10 # Acute none 2 1 1 1.3 sinusitis 2 T.M. 25 # " " 2 2 1 1.7 3 K.H. 44 # " " 1 1 1 1 4 K.A. 20 # Chronic " 2 2 2 2 sinusitis 5 N.N. 36 # " anti- 2 1 1 1.3 biotic 6 Y.E. 62 # " none 1 1 1 1 7 K.Y. 51 # " " 1 1 1 1 8 Y.M. 18 # " " 2 2 2 2 9 T.T. 26 # Post- antibiotic 1 2 1 1.3 operative sinusitis 10 S.O. 42 # " none 2 1 2 1.7 (Three weeks after the treatment was started) No. Subjective Pathological; X-ray Average symptom observation 1 4 2 2 2.7 2 4 4 2 3.3 3 2 2 2 2 5 Same as above 2 2 1 1.7 6 2 2 1 1.7 7 2 2 2 2 8 2 2 2 2 9 2 4 2 2.7 10 4 2 2 2.7 As seen in the tables, when the present preparation was used for the ten patients, said preparation proved to be remarkably effective for the treatment of the sinusitis in one of the patients; effective in six patients; and slightly effective in two patients. Further, in this example, no case was observed in which the present preparation was ineffective in all of the three items of the examination.
Example 2 Patients treated: 10 patients suffering from hemorrhoids who were mainly afflicted with pain, swelling or bleeding (16 - 60 years old).
Methods of Application: (A)....the dried cells water content: 2%) of a Lactobacillus strain having the necessary morphology and nutritional properties and additionally which was resistant to tetracycline. The preparation was administered orally 5 times a day (Dose: 3 g per each time).
(B)....The same preparation was mixed with half its volume of an ointment and applied to the affected part 5 times a day.
(C)....An ointment containing tetracycline was applied to an affected part prior to application of the present preparation.
The tests were first carried out by the following three methods; i.e., (C) + (A), (C) + (B) and (C) + (B) + (A).
Judgement as to their effects: Based on the subjective symptoms and the secondary observations such as subjective pain, bleeding, swelling, the degree of hemorrhoidal nodule and a sense of incongruity at the anus, the therapeutic effects was ranked as +4 (remarkably effective), +2 (effective), +1 (slightly effective), 0 (ineffective) and-2 (aggravated).
The therapeutic effects were observed in 7th, 14th, and 21th day. Further, Table 11 shows the results which were carried out according to (A) + (B) + (C) and were estimated in 7th and 21th day after the treatment was started.
TABLE 11 (One week after the treatment was started) Subjective Degree of Feeling of Average Name pain Bleeding Swelling hemorrho- Discomfort idal nodule Y.T. 1 1 1 1 1 1 K.H. 2 2 1 1 1 1.4 M.M 4 4 2 2 2 2.8 T.S. 1 1 1 1 1 1 T.H. 1 1 1 1 1 1 K.M. 2 1 1 1 1 1.2 M.O. 2 2 2 2 1 1.8 S.S. 1 1 1 1 1 1 N.H. 1 2 1 2 1 1.4 T.Y. 1 1 1 1 1 1 The results were characteristic in that there was not observed any cases of "ineffective" and "aggravated" (Three weeks after the treatment was started) Subjective Degree of Feeling of Average Name pain Bleeding Swelling hemorrho- Discomfort idal nodule Y.T. 2 2 2 2 2 2 K.H. 2 2 2 2 2 2 M.M. 4 4 4 2 4 3.6 T.S. 1 1 1 1 1 1 T.H. 2 2 2 2 2 2 K.N. 2 2 2 2 1 1.8 M.O. 4 4 2 2 2 2.8 S.S. ' 2 1 1 1 1 1.2 N.H. 2 2 2 2 2 2 T.Y. 2 1 1 1 1 1.2 The characteristics of this test results was that there was no case which showed ''4 or "0" in all of the five examination items.
Example 3 Table 12 shows the result of the clinical tests which were carried out in the field of the dentistry by the use of the present preparation. The tests were carried out by (i) packing it (2% dried cells) directly into the affected part, (ii) suspending the present preparation in a physiological saline solution, and then injecting said solution with a syringe, (iii) gargling the throat with an aqueous suspension of the present preparation, or (iv) applying an ointment containing the present preparation to the effected art.
The results were indicated as +++ (remarkably effective), ++ (fairly effective,+ (effective) and -(ineffective).
TABLE 12 No. Name of Sex Age Position Method of Method of Effects patient and operation administration symptom 1 K.S. d 37 1) gingival Extraction (i) ++ abscess of tooth 2 T.A. cf 25 1) " none (ii) + 3 H.O. # 46 6) alveolar none (iv) abscess 4 E.M. 9 22 8) none (iv) ++ 5 S.I. d 19 8/8 periodon Extraction (i) ++ titis of tooth 6 T.H. # 40 7) " " (ii) + 7 T.M. d 57 8) wisdom " (iii) ++ tooth inflamm ation 8 S.N. d 60 8/8 " none (iv) 9 M.N. cos 21 6) gingival none (iii) ++ abscess 10 S.T. cr 34 1) " none (ii) ++ 11 M.K. 9 30 7) " Extraction (i) + of tooth 12 M.M. y 27 8) pulpitis " (i) + As is clear from the table, the high therapeutic effects were observed in almost all of the patients.
Example 4 The present preparation was used for the treatment of the pudendal laceration and the swelling or pain shown after pudendal operations. That is, in the tests on ointment containing the preparation was applied to the affected part several times a day. Further. in the case of heavy laceration, the present preparation was used together with antibiotics and protease. The results are shown in Table 13.
TABLE 13 No. Name Age Child Symptoms Degree Degree Sewing A* T** Observation birth of of up (g/day) (times swell- pain ing 1 W.M. 26 first pudendal ++ ++ pudendal 3 5 2 days later: lacera- vagina swelling and tion pain alleviated; good sewing up 2 K.K. 34 " " + " " " " 3 M.A. 30 " " ++ " " " 4 2 days later; swelling alleviated.
4 days later: pain alleviated; good sewing up 4 J.S. 21 " " ++ " " " 5 " 5 M.M. 29 " incision ++ " " 3 4 " of (antipudenda biotic and protease) Note: A* : Amount applied (g/day) T** : Number of times applied (times/day) The treatment was effective in all of the five patients.
They convalesced satisfactorily.
Despite the discovery of strong antibiotics, the above-mentioned diseases still belong to a group of diseases which are recognized as being difficult to cure. Accordingly, it is inferred that the present preparation is equally applicable to other infectious diseases which are induced by substantially the same mechanisms as the above-mentioned ones.
Example 5 After appendectomy, the present preparation was used for the removal of pathogenic bacteria, fibrin produced at the local section, dead tissues, pus and so forth, or for the treatment of pathogenic bacteria-induced gastritis and enteritis. Said preparation was administered orally and, in almost all cases, together with antibiotics. In comparison untreated patients, the results were indicated as +++ (remarkably effective), ++ (fairly effective), + (effective) and - (ineffective). The Lactobacillus strain used in their experiments was one which is also resistant to the antibiotics used, and in the case of adult patients, the present preparation (the fresh cultivation broth) was administered 8 times a day at a dosage each time of 3 ml/kg of body weight.
TABLE 14 No. Sex Age Name of Remarks Conditions after Effects operation the operation 1 # 38 removal of good ++ appendix 2 # 57 " " + 3 # 40 " " + 4 # 29 " " ++ 5 # 35 enteritis Vibrio " ++ 6 # 32 " " " + 7 d 18 " Salmonella " + 8 cS 24 " 24 Table 14 clearly shows that all the patients convalesced satisfactorily and the present preparation had a good therapeutic effect. Although it sometimes happens in appendicitis cases that the wound could not be sewn up well or the surgical operation had to be repeated because of distribution of bacteria around the affected part or the insufficient inhibitory effects of antibiotics used against bacteria, such incidents were not observed during the experiments shown in the tables or during other various experiments connected therewith.
From the foregoing, it will be manifest that the Lactobacillus strain(s) used in the preparation according to the present invention can be isolated from other Lactobacilli by a technique which includes subjecting the Lactobacilli mixture to nutrient conditions under which strains other than the required Lactobacilli strains do not grow but under which the required stains do grow.
In this Specification, the F.R.I. Nos. 1946, 2779, 2780, 2781 and 2782 refer to the deposit numbers of the microorganisms at the Fermentation Research Institute where thev are referred to officially as Form P Nos. 1946, 2779, 2780, 2781 and 2782, respectively.
Attention is drawn to the specification and claims of our copending British Patent Application No. 21344/77 which relates to compositions useful for culturing and storing a Lactobacillus strain and to a deodorizing composition containing living cells of a Lactobacillus strain.

Claims (7)

WHAT WE CLAIM IS;
1. A pharmaceutical Lactobacilliis preparation useful for the prevention of infection or inflammation or combatting of inflammation of infectious disease comprising one or more strains of live Lactobacillus whose growth is enabled or promoted by addition of one or more of sodium sulphide, ammonia and acetic acid to at least one of Stephenson-Whetham medium, Stephenson-Whetham medium containing vitamins and Stephenson-Whetam medium containing cassamino acid, said preparation being substantially free of other bacterial strains.
2. A pharmaceutical Lactobacllhis useful for the prevention of infection or inflammation or combatting of inflammation or infectious disease preparation comprising one or more strains of live Lactobacillus whose growth is enabled or promoted by addition of one or more of sodium sulphide. ammonia and acetic acid to at least one of Stephenson Whetham medium, Stephenson-Whetham medium containing vitamins and Stephenson Whetham medium containing casamino acid: and a carrier and/or excipient.
3. A preparation as claimed in Claim 1 or 2, wherein said strains of Lactobacillus can grow in the presence of bile.
4. A preparation as claimed in any preceding claim, wherein said strains of Lactobacillus show antibiotic production.
5. A preparation as claimed in any preceding claim, wherein said strains of Laaobaciluscan grow in the presence of antibiotics.
6. A preparation as claimed in Claim 1 or 2, wherein said strains of Lactobacillus is/are one or more of the strains 1946/F.R.I., 2779/F.R.I., 2780/F.R.I., 2781/F.R.I., and 2782/F.R.I.
7. A method of treatment of a non-human mammal for the prevention of infection or inflammation or combatting of inflammation or infectious disease, comprising administering a preparation as claimed in any preceding claim to said non-human mammal.
GB35599/77A 1977-08-24 1977-08-24 Pharmaceutical lactobacillus preparations Expired GB1585863A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB35599/77A GB1585863A (en) 1977-08-24 1977-08-24 Pharmaceutical lactobacillus preparations

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB35599/77A GB1585863A (en) 1977-08-24 1977-08-24 Pharmaceutical lactobacillus preparations

Publications (1)

Publication Number Publication Date
GB1585863A true GB1585863A (en) 1981-03-11

Family

ID=10379520

Family Applications (1)

Application Number Title Priority Date Filing Date
GB35599/77A Expired GB1585863A (en) 1977-08-24 1977-08-24 Pharmaceutical lactobacillus preparations

Country Status (1)

Country Link
GB (1) GB1585863A (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006793A1 (en) * 1988-01-25 1989-07-27 Mallinckrodt, Inc. Container for liquid observed for impurities
WO1989011858A1 (en) * 1988-06-09 1989-12-14 Whitecliffe Laboratories Limited Treatment of immunodeficiency
WO1991005850A1 (en) * 1989-10-10 1991-05-02 Tartusky Gosudarstvenny Universitet Bacterium strain lactobacillus plantarum 38 for production of a bacterial biological preparation
WO1991005851A1 (en) * 1989-10-10 1991-05-02 Tartusky Gosudarstvenny Universitet Bacterium strain lactobacillus casei subsp. casei 37 for production of a bacterial biological preparation
WO2003022255A2 (en) * 2001-09-05 2003-03-20 Vsl Pharmaceuticals, Inc. Lactic acid bacteria comprising unmethylated cytosine-guanine dinucleotides for use in therapy
US7863033B2 (en) 2003-07-30 2011-01-04 Bhph Company Limited Lactobacillus living body activating Lactobacillus preparation and preventive or therapeutic agent for living body infection

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006793A1 (en) * 1988-01-25 1989-07-27 Mallinckrodt, Inc. Container for liquid observed for impurities
WO1989011858A1 (en) * 1988-06-09 1989-12-14 Whitecliffe Laboratories Limited Treatment of immunodeficiency
WO1991005850A1 (en) * 1989-10-10 1991-05-02 Tartusky Gosudarstvenny Universitet Bacterium strain lactobacillus plantarum 38 for production of a bacterial biological preparation
WO1991005851A1 (en) * 1989-10-10 1991-05-02 Tartusky Gosudarstvenny Universitet Bacterium strain lactobacillus casei subsp. casei 37 for production of a bacterial biological preparation
WO2003022255A2 (en) * 2001-09-05 2003-03-20 Vsl Pharmaceuticals, Inc. Lactic acid bacteria comprising unmethylated cytosine-guanine dinucleotides for use in therapy
WO2003022255A3 (en) * 2001-09-05 2003-10-23 Simone Claudio De Lactic acid bacteria comprising unmethylated cytosine-guanine dinucleotides for use in therapy
US7863033B2 (en) 2003-07-30 2011-01-04 Bhph Company Limited Lactobacillus living body activating Lactobacillus preparation and preventive or therapeutic agent for living body infection

Similar Documents

Publication Publication Date Title
US4314995A (en) Pharmaceutical lactobacillus preparations
Ahmadsyah et al. Treatment of tetanus: an open study to compare the efficacy of procaine penicillin and metronidazole.
Whitlock et al. The medicinal leech and its use in plastic surgery: a possible cause for infection
JP3186202B2 (en) Parent organism
Poth Intestinal antisepsis in surgery
Bliss et al. Observations on the Mode of Action of Sulfanilamide
MXPA06001167A (en) Novel lactobacillus, living body activating lactobacillus preparation and preventive or therapeutic agent against living body infection
JP2019526258A (en) Leuconostoc forzapferii strain having alopecia prevention, hair growth promotion or sexual function improvement and composition containing the same
CN109985069B (en) Probiotic compositions and uses thereof
Thormar Antibacterial effects of lipids: historical review (1881 to 1960)
Sborov et al. Bacteriology of the human liver
GB1585863A (en) Pharmaceutical lactobacillus preparations
JPH07108857B2 (en) Bacterial preparations for the prevention and treatment of inflammatory processes and allergic diseases
CN115607577B (en) Probiotics with efficacy of relieving stomatitis, and preparation method and application thereof
DE2738652C3 (en) Lactobacillus Preparation And Its Use In Fighting Bacterial Infection And Inflammation
Rosenberg et al. Antibiotic TA: an adherent antibiotic
RU2354392C1 (en) Remedy for treating bacterial vaginosis and method of bacterial vaginosis treatment
CN100388949C (en) Lysostaphin freeze dried powder used for preventing and treating cattle edometritis
CHANDLER et al. Osteomyelitis Of The Femoral Neck And Head
Sim Anaerobic infections
CA1104929A (en) Pharmaceutical lactobacillus preparations
RU2367454C1 (en) Intime hygiene product &#34;femivit&#34;
RU2602692C1 (en) Method of treating chronic pharyngitis
RU2248212C2 (en) Preparation for treatment of bacterial vaginitis, method for its preparing and method for treatment of bacterial vaginitis
Iyengar et al. Plumbago zeylanica L.(Chitrak) a gastrointestinal flora normaliser

Legal Events

Date Code Title Description
PS Patent sealed
PCNP Patent ceased through non-payment of renewal fee

Effective date: 19950824